Angiogenesis and Anti-Angiogenic Molecularly Targeted Therapies in Malignant Gliomas

Oncology

Volumn 77, Issue 1, 2009, Pages 1-11

  Argyriou, Andreas A ^a   Giannopoulou, Efstathia ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Angiogenesis; Angiogenic switch; Malignant gliomas; Monoclonal antibodies; Tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR; IMATINIB; IODINE 123; IRINOTECAN; MONOCLONAL ANTIBODY DC101; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ATAXIA; BLEEDING; BLOOD TOXICITY; BLOOD VESSEL PERMEABILITY; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CELL COMMUNICATION; DEEP VEIN THROMBOSIS; DRUG RECEPTOR BINDING; EMBOLISM; EPISTAXIS; FATIGUE; GLIOBLASTOMA; GLIOMA; HEADACHE; HEART INFARCTION; HEREDITY; HUMAN; HYPERTENSION; HYPOXIA; LEUKOENCEPHALOPATHY; LUNG EMBOLISM; MOLECULAR THERAPY; PATHOGENESIS; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; STOMATITIS; STROKE; THROMBOEMBOLISM; TUMOR BLEEDING; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; BRAIN TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 65549093775     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218165     Document Type: Review

References (98)

1. Argyriou AA, Antonacopoulou A, Iconomou G, Kalofonos HP: Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 2009;69:199-210. DOI: 10.1016/j.critrevonc. 2008.05.005
2. Leon SP, Folkerth RD, Black PM: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-372.
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
4. Semenza GL: Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 2007;10 2:840 -847.
5. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
6. Rong Y, Durden DL, Van Meir EG, Brat DJ: 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-539.
7. Jouanneau E: Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 2008;62:31-52.
8. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D: Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005;15: 297-310.
9. Forsythe JA, Jiang BH, Iyer N V, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cel l Biol 1996;16:4604-4613.
10. Munaut C, Boniver J, Foidart JM, Deprez M: Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol 2002;28:452-460.
11. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG: Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004;70:229-243.
12. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP: Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/ p15) in primary astrocytic tumours. Br J Cancer 1997;75:2-8.
13. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP: The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 1998;51:1250-1255.
14. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology 2005;25: 1-7.
15. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
16. Kargiotis O, Rao JS, Kyritsis AP: Mechanisms of angiogenesis in gliomas. J Neurooncol 2006;78:281-293.
17. Chi A, Norden AD, Wen PY: Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007;7:1537-1560.
18. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, et al: Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10-18.
19. Bouloumie A, Schini-Kerth VB, Busse R: Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999;41:773-780.
20. Wang W, Merrill MJ, Borchardt RT: Vascular endothelial growth factor affects permeability of brain microvessel endothelial cells in vitro. Am J Physiol 1996;271:C1973-C1980.
21. Machein MR, Plate KH: VEGF in brain tumors. J Neurooncol 2000;50:109-120.
22. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
23. Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML, et al: Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 2005;12:229-241.
24. Rak J, Kerbel RS: Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001;333:267-283.
25. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-28228.
26. L oef f ler S, Fay a rd B, Weis J, Weis senberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 2005;115:202-213.
27. Tsai JC, Goldman CK, Gillespie GY: Vascular endothelial growth factor in human glio-ma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995;82:864-873.
28. Holmgren L, Glaser A, Pfeifer-Ohlsson S, Ohlsson R: Angiogenesis during human extraembryonic development involves the spa-tiotemporal control of PDGF ligand and receptor gene expression. Development 1991;113:749-754.
29. Ranza E, Facoetti A, Morbini P, et al: Exogenous platelet-derived growth factor (PDGF) induces human astrocytoma cell line proliferation. Anticancer Res 2007;27:2161-2166.
30. Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 1992;67:529-534.
31. Brockmann MA, Ulbricht U, Grüner K, Fillbrandt R, Westpha l M, Lamszus K: Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003;52:1391-1399.
32. Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF: Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 1992;70:2673-2680.
33. Dunn IF, Heese O, Black PM: Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000;50:121-137.
34. Zagzag D: Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 1995;14 6:293-309.
35. Funakoshi H, Nakamura T: Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 2003;327:1-23.
36. Kunkel P, Müller S, Schirmacher P, Stavrou D, Fillbrandt R, Westphal M, La mszus K:Expression and localization of scatter factor/ hepatocyte growth factor in human astrocytomas. Neuro Oncol 2001;3:82-88.
37. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TP: Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2003;23:69-75.
38. Brockmann MA, Papadimitriou A, Brandt M, Fi llbrandt R, Westpha l M, La mszus K: Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/he-patocyte growth factor-antagonist NK4. Clin Cancer Res 2003;9:4578-4585.
39. Feld kamp M M, Lau N, Guha A: Signal trans-duction pathways and their relevance in human astrocytomas. J Neurooncol 1997;35: 223-248.
40. Nakamura JL: The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications. Expert Opin Ther Targets 2007;11:463-472.
41. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-2294.
42. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG: The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005;118:771-780.
43. Péoch M, Farion R, Hiou A, Le Bas JF, Pasquier B, Rémy C: Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Res 2002;22:2147-2151.
44. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP: Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004;10:2072-2081.
45. Brat DJ, Bellail AC, Van Meir EG: The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neurooncol 2005;7:122-133.
46. Choi C, Gillespie GY, Van Wagoner NJ, Benveniste EN: Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol 2002;56:13-19.
47. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM: Alpha(m)beta3 and alpha(m)beta5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-309.
48. Levicar N, Strojnik T, Kos J, Dewey RA, Pilkington GJ, Lah TT: Lysosomal enzymes, catrepsins in brain tumour invasion. J Neurooncol 20 02;58:21-32.
49. Wang M, Tang J, Liu S, Yoshida D, Teramoto A: Expression of cathepsin B and microvascular density increases with higher grade of astrocy tomas. J Neurooncol 2005;71:3-7.
50. Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA: Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995;55:907-914.
51. Takano S, Tsuboi K, Matsumura A, Nose T: Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts. Neuro Oncol 2003;5: 1-7.
52. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-6628.
53. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M: Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelialcadherin. Clin Cancer Res 2005;11:4934-4940.
54. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563.
55. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005;19(suppl 3):7-16.
56. Goldbrunner RH, Bendszus M, Wood J, et al: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004;55:426-432.
57. Polyzos A: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 2008;108:261-266.
58. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007;9:412-423.
59. Argyriou A, Giannopoulou E, Dimitrakopoulos F, Kalofonos H: Announcement and preliminary results of the effects of sunitinib and/or lapatinib on U87 glioma cell lines. Ann Oncol 2008;19(suppl 8):58.
60. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-4016.
61. Eller JL, Longo SL, Kyle MM, et al: Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005;56:155-162.
62. Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, et al: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11:7841-7850.
63. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, et al: alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002;98:690-697.
64. Norden AD, Drappatz J, Wen PY: Novel antiangiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-1160.
65. Kosmas C, Kalofonos H, Epenetos AA: Monoclonal antibodies. Future potential in cancer chemotherapy. Drugs 1989;38:645-657.
66. Sathornsumetee S, Rich JN: Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007;13:3545-3558.
67. Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007;6:1909-1919.
68. Sadones J, Chaskis E, Joosens EJ, et al: A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: preliminary results. Proc Am Soc Clin Oncol 2006;24:18S, abstr. 1558.
69. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142.
70. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, et al: Gefitinib in patients with progressive highgrade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007;96:1047-1051.
71. Krishnan S, Brown PD, Ballman KV, et al: Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multi-forme: results of North Central Cancer Treatment Group protocol N0177. Int J Ra-diat Oncol Biol Phys 2006;65:1192-1199.
72. Prados MD, Lamborn KR, Chang S, et al: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8:67-78.
73. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, et al: Phase II study of carboplatin and erlotinib (Tarce-va, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 2008;90:89-97.
74. Mellinghoff IK, Wang MY, Vivanco I, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024.
75. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-887.
76. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006;32:74-89.
77. Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, et al: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989;30:1636-1645.
78. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25: 4722-4729.
79. Bokstein F, Shpigel S, Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267-2273.
80. Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, et al: Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-7073.
81. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, et al: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilit y. Int J Radiat Oncol Biol Phys 2008;71:1372-1380.
82. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vascula-ture and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
83. Conrad C, Friedman H, Reardon D, et al: A phase I/II trial of single-agent PTK787/ ZK222584, a novel oral angiogenesis inhibitor, in patients with recurrent GBM. J Clin Oncol 20 0 4 ASCO A nnu Meet Proc 20 04;22:abstr. 1512.
84. Wen PY, Yung WK, Lamborn KR, et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006;12:4899-4907.
85. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, et al;European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008;26:4659-4665.
86. Desjardins A, Quinn JA, Vredenburgh JJ, et al: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III maligna nt g liomas. J Neurooncol 2007;83:53-60.
87. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP: Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 2007;27:4255-4257.
88. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH: Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007;106:601-608.
89. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF: Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008;10:355-360.
90. Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors;a review. Eur J Cancer 2006;42:3127-3139.
91. Norden AD, Drappatz J, Wen PY: Novel antiangiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-1160.
92. Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, et al: Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 2008;164:588-594.
93. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH: Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003;49:848-855.
94. Kaminogo M, Ishimaru H, Morikawa M, Ochi M, Ushijima R, Tani M, Matsuo Y, Kawakubo J, Shibata S: Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 2001;43:353-363.
95. Schaller BJ, Cornelius JF, Sandu N, Buchfelder M: Molecular imaging of brain tumors personal experience and review of the literature. Curr Mol Med 2008;8:711-726.
96. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, et al: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-579.
97. Kang HW, Torres D, Wald L, Weissleder R, Bogdanov AA Jr: Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab Invest 2006;86:599-609.
98. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC: Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4:623-626.